Submissions from 2021
The LEAP program: lenvatinib plus pembrolizumab for the treatment of advanced solid tumors., Matthew H Taylor, Emmett V Schmidt, Corina Dutcus, Elaine M Pinheiro, Yasuhiro Funahashi, Gregory Lubiniecki, and Drew Rasco
Correlation of Performance Status and Neutrophil-Lymphocyte Ratio With Efficacy in Radioiodine-Refractory Differentiated Thyroid Cancer Treated With Lenvatinib., Matthew H Taylor, Shunji Takahashi, Jaume Capdevila, Makoto Tahara, Sophie Leboulleux, Naomi Kiyota, Corina E Dutcus, Ran Xie, Bruce Robinson, Steven I Sherman, Mouhammed Amir Habra, Rossella Elisei, and Lori J Wirth
Intratumoral Plasmid IL12 Expands CD8, Melinda L Telli, Hiroshi Nagata, Irene Wapnir, Chaitanya R Acharya, Kaitlin Zablotsky, Bernard A Fox, Carlo Bifulco, Shawn M. Jensen, Carmen Ballesteros-Merino, Mai Hope Le, Robert H Pierce, Erica Browning, Reneta Hermiz, Lauren Svenson, Donna Bannavong, Kim Jaffe, Jendy Sell, Kellie Malloy Foerter, David A Canton, Christopher G Twitty, Takuya Osada, H Kim Lyerly, and Erika J Crosby
Abemaciclib in Combination With Endocrine Therapy for Patients With Hormone Receptor-Positive, HER2-Negative Metastatic Breast Cancer: A Phase 1b Study., Sara M Tolaney, Muralidhar Beeram, J Thaddeus Beck, Alison Conlin, E Claire Dees, Shannon L Puhalla, Brent N Rexer, Howard A Burris, Komal Jhaveri, Teresa Helsten, Carlos Becerra, Kevin Kalinsky, Kathleen N Moore, Allison M Manuel, Andrew Lithio, Gregory L Price, Sonya C Chapman, Lacey M Litchfield, and Matthew P Goetz
583 Exploring the potential of T cell acute lymphoblastic leukemia (T-ALL) for generating leukemia-specific T cell responses that can be therapeutically harnessed with immunotherapy, Todd Triplett, Andrew D Weinberg, and See full list of authors in comments
Supportive Management of Patients with Advanced Pheochromocytomas and Paragangliomas Receiving PRRT., Erica S Tsang, Gayle Funk, Janet Leung, Grace Kalish, and Hagen F Kennecke
Associations of Uncertainty With Psychological Health and Quality of Life in Older Adults With Advanced Cancer., Haydee C Verduzco-Aguirre, Dilip Babu, Supriya G Mohile, Javier Bautista, Huiwen Xu, Eva Culakova, Beverly Canin, Yingzi Zhang, Megan Wells, Ronald M Epstein, Paul Duberstein, Colin McHugh, William Dale, Alison Conlin, James Bearden, Jeffrey Berenberg, Mohamedtaki Tejani, and Kah Poh Loh
Enriching for Tumor-Reactive CD8 TIL with CD39/103 Markers: Implications for TIL Therapy, Andrew D. Weinberg
Adipocytes as Anticancer Drug Delivery Depot, D Wen, J Wang, and Z Gu
Tumor Microenvironment, HLA Class I and APM Expression in HPV-Negative Oral Squamous Cell Carcinoma., Claudia Wickenhauser, Daniel Bethmann, Matthias Kappler, Alexander Walter Eckert, André Steven, Jürgen Bukur, Bernard Aloysius Fox, Jana Beer, and Barbara Seliger
Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts., Selina K. Wong, Jennifer G. Whisenant, Rachel E Sanborn, and See list of authors in comments
Effects of radiation on tumor vasculature., Tomoko Yamazaki and Kristina H Young
Submissions from 2020
Characterization of a Novel Compound That Stimulates STING-Mediated Innate Immune Activity in an Allele-Specific Manner., Jinu Abraham, Sara Botto, Nobuyo Mizuno, Kara Pryke, Bryan Gall, Dylan Boehm, Tina M Sali, Haihong Jin, Aaron Nilsen, Michael J. Gough, Jason R Baird, Marita Chakhtoura, Caroline Subra, Lydie Trautmann, Elias K Haddad, and Victor R DeFilippis
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma., Alain P Algazi, Christopher G Twitty, Katy K Tsai, Mai Le, Robert Pierce, Erica Browning, Reneta Hermiz, David A Canton, Donna Bannavong, Arielle Oglesby, Murray Francisco, Lawrence Fong, Mikael J Pittet, Sean P Arlauckas, Christopher Garris, Lauren P Levine, Carlo Bifulco, Carmen Ballesteros-Merino, Shailender Bhatia, Sharron Gargosky, Robert H I Andtbacka, Bernard A Fox, Michael D Rosenblum, and Adil I Daud
Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma., Alain P Algazi, Christopher G Twitty, Katy K Tsai, Mai Le, Robert Pierce, Erica Browning, Reneta Hermiz, David A Canton, Donna Bannavong, Arielle Oglesby, Murray Francisco, Lawrence Fong, Mikael J Pittet, Sean P Arlauckas, Christopher Garris, Lauren P Levine, Carlos Bifulco, Carmen Ballesteros-Merino, Shailender Bhatia, Sharron Gargosky, Robert H I Andtbacka, Bernard A Fox, Michael D Rosenblum, and Adil I Daud
Intracellular Galectin-3 Is Essential for OX40-Mediated Memory CD8, Mohammad Farhad Amani, Annah S Rolig, and William L. Redmond
Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies, Ian Churchill Anderson, Yinghui Wang, Zejing Wang, and Rachel E Sanborn
Sgnlva-005: Open-label, phase II study of ladiratuzumab vedotin (LV) for advanced aerodigestive tract malignancies., Ian Churchill Anderson, Yinghui Wang, Zejing Wang, and Rachel E Sanborn
Safety and activity of varlilumab, a novel and first-in-class agonist anti-CD27 antibody, for hematologic malignancies., Stephen M Ansell, Ian Flinn, Matthew H Taylor, Branimir I Sikic, Joshua Brody, John Nemunaitis, Andrew Feldman, Thomas R Hawthorne, Tracey Rawls, Tibor Keler, and Michael J Yellin
Phase II Trial of Carfilzomib Plus Irinotecan in Patients with Small Cell Lung Cancer Who Have Progressed on Prior Platinum-Based Chemotherapy., Susanne M. Arnold, Kari Chansky, Maria Q. Baggstrom, Michael A. Thompson, Rachel E Sanborn, John L. Villano, Saiama N. Wagar, John Hamm, Markos Leggas, Maurice Willis, Joseph Rosales, and John J. Crowley
The Great Debate at 'Immunotherapy Bridge', Naples, December 5, 2019., Paolo A Ascierto, Carlo Bifulco, Jerome Galon, Claus Garbe, Samir N Khleif, Jennifer McQuade, Kunle Odunsi, Hideho Okada, Chrystal M Paulos, Sergio A Quezada, Hussein A Tawbi, John Timmerman, Giorgio Trinchieri, Lisa H Butterfield, and Igor Puzanov
Insights from immuno-oncology: The Society for Immunotherapy of Cancer statement on access to IL-6-targeting therapies for COVID-19, Paolo A. Ascierto; Bernard A Fox; Walter Urba; Ana Carrizosa Anderson; Michael Atkins; Ernest C. Borden; Julie R. Brahmer; Lisa H. Butterfield; Alessandra Cesano; Daniel S. Chen; Tanja D. De Gruijl; Robert O. Dillman; Charles G. Drake; Leisha A. Emens; Thomas F. Gajewski; James L. Gulley; F Stephen Hodi, Jr.; Patrick Hwu; David Kaufman; Howard L. Kaufman; Michael T. Lotze; Francesco M. Marincola; Kim A. Margolin; Michael J. Mastrangelo; Marcela V. Maus; Douglas G. McNeel; David R. Parkinson; Pedro J. Romero; Paul M. Sondel; Stefani Spranger; Mario Sznol; George J. Weiner; Jon M. Wigginton; and Jeffrey S. Weber
No time to die: the consensus immunoscore for predicting survival and response to chemotherapy of locally advanced colon cancer patients in a multicenter international study., Paolo A Ascierto, Francesco M Marincola, Bernard A Fox, and Jérôme Galon
Perspectives in melanoma: meeting report from the "Melanoma Bridge" (December 5th-7th, 2019, Naples, Italy)., Paolo A Ascierto, Igor Puzanov, Sanjiv S Agarwala, Christian Blank, Richard D Carvajal, Sandra Demaria, Reinhard Dummer, Marc Ernstoff, Soldano Ferrone, Bernard A Fox, Thomas F Gajewski, Claus Garbe, Patrick Hwu, Roger S Lo, Georgina V Long, Jason J Luke, Iman Osman, Michael A Postow, Ryan J Sullivan, Janis M Taube, Giorgio Trinchieri, Hassane M Zarour, Corrado Caracò, and Magdalena Thurin
Contemporary Techniques in Orbital Reconstruction: A Review of the Literature and Report of a Case Combining Surgical Navigation, Computer-Aided Surgical Simulation, and a Patient-Specific Implant., Iman Azarmehr, Kasper Stokbro, R Bryan Bell, and Torben Thygesen
Outpatient treatment with lisocabtagene maraleucel (liso-cel) across a variety of clinical sites from three ongoing clinical studies in relapsed/refractory (R/R) large B-cell lymphoma (LBCL)., Carlos R. Bachier, John E Godwin, Charalambos Andreadis, Maria Lia Palomba, Jeremy S. Abramson, Alison R. Sehgal, Gerhard Hildebrandt, Don A. Stevens, Daanish Hoda, Edward J. Licitra, Tanya Siddiqi, Thalia Andrea Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, James Lymp, and David G. Mahoney
Outpatient Treatment with Lisocabtagene Maraleucel (liso-cel) in 3 Ongoing Clinical Studies in Relapsed/Refractory (R/R) Large B Cell Non-Hodgkin Lymphoma (NHL), Including Second-Line Transplant Noneligible (TNE) Patients: Transcend NHL 001, Outreach, and PILOT, Carlos R. Bachier, M Lia Palomba, Jeremy S. Abramson, Charalambos Andreadis, Alison Sehgal, John E Godwin, Gerhard C. Hildebrandt, Tanya Siddiqi, Don Stevens, Thalia Farazi, Ana Kostic, Nikolaus S. Trede, Lei Wang, James Lymp, Tennille Thelen, Ken Ogasawara, and David G. Maloney
Improved tolerability of neratinib in patients with HER2-positive early-stage breast cancer: the CONTROL trial., C H Barcenas, S A Hurvitz, J A Di Palma, R Bose, A J Chien, N Iannotti, G Marx, A Brufsky, A Litvak, E Ibrahim, R H Alvarez, M Ruiz-Borrego, N Chan, Y Manalo, A Kellum, M Trudeau, M Thirlwell, J Garcia Saenz, D Hunt, R Bryce, L McCulloch, H S Rugo, D Tripathy, A Chan, CONTROL Study Investigators, and Alison Conlin
Abstract B01: Surgical outcomes following neoadjuvant hypofractionated radiation in combination with nivolumab: High rate of pathologic complete response in patients with p16+ head and neck squamous cell carcinoma, Richard Bryan Bell, Rom Leidner, Marcus Couey, Ashish Patel, Amber L Watters, Hong Ziao, Carlo Bifulco, Brian D. Piening, George Morris, Lessli Rushforth, Dawn Brucker, Shorin Nemeth, Kristina H Young, Michael J. Gough, and Marka R Crittenden
Abstract B01: Surgical outcomes following neoadjuvant hypofractionated radiation in combination with nivolumab: High rate of pathologic complete response in patients with p16+ head and neck squamous cell carcinoma, Richard Bryan Bell, Rom Leidner, Marcus Couey, Ashish Patel, Amber L Watters, Hong Ziao, Carlo Bifulco, Brian D. Piening, George Morris, Lessli Rushforth, Dawn Brucker, Shorin Nemeth, Kristina H Young, Michael J. Gough, and Marka R Crittenden
Cohort Expansion Study of Neoadjvuant Immunoradiotherapy in Locoregionally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma, Richard Bryan Bell, Rom Leidner, Kristina H Young, Brendan Curti, Marcus Couey, Ashish Patel, Amber L Watters, Hong D Xiao, George Morris, Lessli Rushforth, Michael J. Gough, and Marka R Crittenden
Cohort Expansion Study of Neoadjvuant Immunoradiotherapy in Locoregionally Advanced HPV+ and HPV- Head and Neck Squamous Cell Carcinoma, Richard Bryan Bell, Rom Leidner, Kristina H Young, Brendan Curti, Marcus Couey, A Patel, Amber L Watters, Hong D Xiao, G Morris, L Rushforth, Michael J. Gough, and Marka R Crittenden
Development and Preliminary Clinical Activity of PD-1-Guided CTLA-4 Blocking Bispecific DART Molecule., Alexey Berezhnoy, Bradley J Sumrow, Kurt Stahl, Kalpana Shah, Daorong Liu, Jonathan Li, Su-Shin Hao, Anushka De Costa, Sanjeev Kaul, Johanna Bendell, Gregory M Cote, Jason J Luke, Rachel E Sanborn, Manish R Sharma, Francine Chen, Hua Li, Gundo Diedrich, Ezio Bonvini, and Paul A Moore
Heterodimeric IL-15 delays tumor growth and promotes intratumoral CTL and dendritic cell accumulation by a cytokine network involving XCL1, IFN-γ, CXCL9 and CXCL10., Cristina Bergamaschi, Hrishikesh Pandit, Bethany A Nagy, Dimitris Stellas, Shawn M. Jensen, Jenifer Bear, Maggie Cam, Antonio Valentin, Bernard A Fox, Barbara K Felber, and George N Pavlakis
Transcriptional and immunohistological assessment of immune infiltration in pancreatic cancer., Brady Bernard, Venkatesh Rajamanickam, Christopher Dubay, Brian D. Piening, Emilio Alonso, Zeljka Jutric, Ephraim Tang, Pippa Newell, Paul D Hansen, Terry R Medler, Andrew J Gunderson, Kristina H Young, Carlo Bifulco, Joanna Pucilowska, Marka R Crittenden, and Michael J. Gough
Flt3 ligand augments immune responses to anti-DEC-205-NY-ESO-1 vaccine through expansion of dendritic cell subsets, Nina Bhardwaj, Philip A. Friedlander, Anna C. Pavlick, Marc S. Ernstoff, Brian R. Gastman, Brent A. Hanks, Brendan Curti, Mark R. Albertini, Jason J. Luke, Ana B. Blazquez, Sreekumar Balan, Davide Bedognetti, Joseph M. Beechem, Andrea S. Crocker, Leonard D'Amico, Patrick Danaher, Thomas A. Davis, Thomas Hawthorne, Bruce W. Hess, Tibor Keler, Lisa Lundgren, Chihiro Morishima, Nirasha Ramchurren, Darawan Rinchai, Andres M. Salazar, Bob A. Salim, Elad Sharon, Laura A. Vitale, Ena Wang, Sarah Warren, Michael J. Yellin, Mary L. Disis, Martin A. Cheever, and Steven P. Fling
Integrating multiomics in the practice of diagnostic pathology, Carlo Bifulco
72 Routine use of comprehensive genomic profiling to assess tumor mutational burden across a community health system, Carlo Bifulco, Roshanthi Weerasinghe, Bela Bapat, Alexa K Dowdell, Shwetha Pindikuri, Sheila Reynolds, Nancy Biery, David Ball, Mary Campbell, Thomas R. Ward, Alisha Stein, Brock Schroeder, David Eberhard, and Brian D. Piening
72 Routine use of comprehensive genomic profiling to assess tumor mutational burden across a community health system, Carlo Bifulco, Roshanthi Weerasinghe, Bela Bepat, Alexa K Dowdell, Shwetha Pindikuri, Sheila Reynolds, Nancy Biery, David Ball, Mary Campbell, Thomas R. Ward, Alisha Stein, Brock Schroeder, David Eberhard, and Brian D. Piening
Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors and Radiation, Tiffany C. Blair, Shelly Bambina, Alejandro F Alice, Gwen Kramer, Terry R Medler, Jason R Baird, Miranda L. Broz, Garth Tormoen, Victoria Troesch, Marka R Crittenden, and Michael J. Gough
Dendritic Cell Maturation Defines Immunological Responsiveness of Tumors to Radiation Therapy., Tiffany C Blair, Shelly Bambina, Alejandro F Alice, Gwen Kramer, Terry R Medler, Jason R Baird, Miranda L Broz, Garth W Tormoen, Victoria Troesch, Marka R Crittenden, and Michael J. Gough
CX-2009, a CD166-directed probody drug conjugate (PDC): Results from the first-in-human study in patients (Pts) with advanced cancer including breast cancer (BC)., Valentina Boni, Howard A. Burris III, Joyce F. Liu, Alexandra I. Spira, Hendrik-Tobias Arkenau, Mary J. Fidler, Lee S. Rosen, Randy F. Sweis, Nataliya Volodymyrivna Uboha, Rachel E Sanborn, Bert O'Neil, James J. Harding, Patricia LoRusso, Amy M. Weise, Javier Garcia-Corbacho, Ivan Victoria, John W. Frye, Rachel Li, Mark Stroh, and Funda Meric-Bernstam
PANEL DISCUSSION: Future Directions for Adoptive Cell Therapy, Adrian Bot, Andreas Bader, Christina Coughlin, and Andrew D Weinberg
A phase I/II study of HB-201, an arenavirus-based cancer immunotherapy, alone, or in combination with anti-PD-1 in patients with HPV16+ cancers., Bharat Burman, Jiaxin Niu, Rom Leidner, Ding Wang, Debra L. Richardson, Corinne Iacobucci, Andy Hwang, Xiaoping Qing, Igor Matushansky, Dmitriy Zamarin, Alan Loh Ho, David G. Pfister, and Marshall R. Posner
PD-1 Blockade in Anaplastic Thyroid Carcinoma., Jaume Capdevila, Lori J Wirth, Thomas Ernst, Santiago Ponce Aix, Chia-Chi Lin, Rodryg Ramlau, Marcus O Butler, Jean-Pierre Delord, Hans Gelderblom, Paolo A Ascierto, Angelica Fasolo, Dagmar Führer, Marie Luise Hütter-Krönke, Patrick M Forde, Anna Wrona, Armando Santoro, Peter M Sadow, Sebastian Szpakowski, Hongqian Wu, Geraldine Bostel, Jason Faris, Scott Cameron, Andreea Varga, and Matthew H Taylor
1258O Amivantamab (JNJ-61186372), an EGFR-MET bispecific antibody, in combination with lazertinib, a 3rd-generation tyrosine kinase inhibitor (TKI), in advanced EGFR NSCLC, BC Cho, KH Lee, EK Cho, D-W Kim, J-S Lee, J-Y Han, S-W Kim, A Spira, EB Haura, EK Sabari, Rachel E Sanborn, JM Bauml, JE Gomez, P Lorenzini, JR Infante, J Xie, N Haddish-Berhane, M Thayu, RE Knoblauch, and K Park
Impact of chemotherapy (chemo) on t-cell maturation and clonal proliferation in early-stage and metastatic breast cancer, Brie Chun, Joanna Pucilowska, Valerie Conrad, Mark Schmidt, Isaac Kim, Paul Fields, Alison Conlin, Heather McArthur, and David B Page
976TiP SPEARHEAD-2 trial design: A phase II pilot trial of ADP-A2M4 in combination with pembrolizumab in patients with recurrent or metastatic head and neck cancer, EE Cohen, L Dunn, P Neupane, M Gibson, Rom Leidner, P Savvides, N Hyland, T Trivedi, M Dudley, S Biswas, D Williams, and E Norry
Management of Zygomaticomaxillary Complex Fractures Utilizing Intraoperative 3-Dimensional Imaging: The ZYGOMAS Protocol., Karl Cuddy, Eric J Dierks, Allen Cheng, Ashish Patel, Melissa Amundson, and Richard Bryan Bell
Randomized phase II study of stereotactic body radiotherapy and interleukin-2 versus interleukin-2 in patients with metastatic melanoma., Brendan Curti, Marka R Crittenden, Steven K Seung, Christopher B Fountain, Roxanne Payne, ShuChing Chang, Jessica Fleser, Kimberly Phillips, Ian Malkasian, Lyn B Dobrunick, and Walter Urba
Impact of geography and travel distance on outcomes in epithelial ovarian cancer: a national cancer database analysis., Ava Daruvala, F Lee Lucas, Jesse Sammon, Christopher Darus, and Leslie Bradford
368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors, Adi Daub, Brendan Curti, Mehmet Bilen, Andrew Brohl, Evidio Domingo-Musibay, Erkut Borazanci, Christine Fanton, Cat Haglund, Mona Vimal, Mann Muhsin, Mario Marcondes, Anh Nguyen, Mary Tagliaferri, Wei Lin, Jonathan Zalevsky, and Sandra D'Angelo
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study, Adi Daub, Scott Tykodi, Gregory Daniels, Michele Maio, Brendan Curti, Karl Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daneil Cho, Shanhong Guan, Erika Puente, Ute Hoch, Sue Currie, Tuan Nguyen, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Mario Sznol, and Michael Hurwitz
368 REVEAL: Phase 1 dose-escalation study of NKTR-262, a novel TLR7/8 agonist, plus bempegaldesleukin: local innate immune activation and systemic adaptive immune expansion for treating solid tumors, Abi Diab, Brendan Curti, Mehmet Bilen, Andrew Brohl, Evidio Domingo-Musibay, Erkut Borazanci, Christine Falon, Cat Haglund, Mona Vimal, Mann Muhsin, Mario Marcondes, Anh Nguyen, Mary Tagliaferri, Wei Lin, Jonathan Zalevsky, and Sandra D'Angelo
Bempegaldesleukin (NKTR-214) plus Nivolumab in Patients with Advanced Solid Tumors: Phase I Dose-Escalation Study of Safety, Efficacy, and Immune Activation (PIVOT-02)., Adi Diab, Nizar M Tannir, Salah-Eddine Bentebibel, Patrick Hwu, Vassiliki Papadimitrakopoulou, Cara Haymaker, Harriet M Kluger, Scott N Gettinger, Mario Sznol, Scott S Tykodi, Brendan Curti, Mary A Tagliaferri, Jonathan Zalevsky, Alison L Hannah, Ute Hoch, Sandra Aung, Christie Fanton, Ahsan Rizwan, Ernesto Iacucci, Yijie Liao, Chantale Bernatchez, Michael E Hurwitz, and Daniel C Cho
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study, Adi Diab, Scott Tykodi, Gregory Daniels, Michele Maio, Brendan Curti, Karl Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel Cho, Shanhong Guan, Erika Puente, Ute Hoch, Sue Currie, Tuan Nguyen, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Mario Sznol, and Michael Hurwitz
420 Progression-free survival and biomarker correlates of response with BEMPEG plus NIVO in previously untreated patients with metastatic melanoma: results from the PIVOT-02 study, Adi Diab, Scott Tykodi, Gregory Daniels, Michele Maio, Brendan Curti, Karl Lewis, Sekwon Jang, Ewa Kalinka, Igor Puzanov, Alexander Spira, Daniel Cho, Shanhong Guan, Erika Puente, Ute Hoch, Sue Currie, Tuan Nguyen, Wei Lin, Mary Tagliaferri, Jonathan Zalevsky, Mario Sznol, and Michawl Hurwitz
Genomic heterogeneity and clinical characterization of SARS-CoV-2 in Oregon, Alexa K Dowdell, Kevin Matlock, Fred L. Robinson, Roshanthi Weerasinghe, Rogan Rattray, Marina Pukay, Melvin Lathara, Anastacia Harlan, Thomas R. Ward, Mary Campbell, Walter Urba, Ganapati Srinivasa, Carlo Bifulco, and Brian D. Piening
A phase II, open-label study of tomivosertib (eFT508) added on to continued checkpoint inhibitor therapy in patients (pts) with insufficient response to single-agent treatment., Anthony B. El-Khoueiry, Nishan Tchekmedyian, Rachel E Sanborn, Julio Antonio Peguero, Kerry Pulver, Vekas Dembla, Jacob Stephen Thomas, Gary Gene Chiang, Mark Densel, Neil Sankar, Stephen Theodore Worland, Lyon L. Gleich, and Robert S. Sikorski
418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors, Cathy Eng, Joaquina Baranda, Matthew H Taylor, Michael Gordon, Ursula Matulonis, Filip Janku, Martin Kornacker, Asha Kamat, Oliver Rosen, and Antonio Jimeno
418 A phase 1, dose escalation and dose expansion study of SQZ PBMC HPV as monotherapy and in combination with atezolizumab in HLA-A*02+ Patients with HPV16+ recurrent, or metastatic solid tumors, Cathy Eng, Joaquina Baranda, Matthew H Taylor, Michael Gordon, Ursula Matulonis, Filip Janku, Martin Kornacker, Asha Kamat, Oliver Rosen, and Antonio Jimeno
Real-world burden of myelosuppression in patients with small cell lung cancer (SCLC): Retrospective, longitudinal data analysis., Robert S. Epstein, JoAnn Krenitsky, Roshanthi Weerasinghe, Amy S. Parrish, Rachel E Sanborn, and Tehseen Salimi
799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data, Pablo Fernandez-Penas, Matteo Carlino, Katy Tsai, Victoria Atkinson, Monaster Shaheen, Sajeve Thomas, Catalin Mihalcioiu, Tom Van Hagen, Rachel Roberts-Thomson, Andrew Haydon, Andrew Mant, Marcus Butler, Gregory Daniels, Elizabeth Buchbinder, John Hyngstrom, Mecker Moller, Igor Puzanov, C Lance Cowey, Eric Whitman, Carmen Ballesteros-Merino, Shawn M. Jensen, Bernard A Fox, Emmett Schmidt, Clemens Krepler, Scott Diede, Erica Browning, Reneta Hermiz, Lauren Svenson, Jon Salazar, Jack Lee, Christopher Baker, Donna Bannavong, Jendy Sell, Kellie Malloy Foerter, David Canton, Sandra Aung, Christopher Twitty, Alain Algazi, and Adil Daud
799 Durable responses and immune activation with intratumoral electroporation of pIL-12 plus pembrolizumab in actively progressing anti-PD-1 refractory advanced melanoma: KEYNOTE 695 interim data, Pablo Fernandez-Penas, Matteo Carlino, Katy Tsai, Victoria Atkinson, Monater Shaheen, Sajeve Thomas, Catalin Mihalcioiu, Tom Van Hagen, Rachel Roberts-Thomson, Andrew Haydon, Andrew Mant, Marcus Butler, Gregory Daniels, Elizabeth Buchbinder, John Hyngstrom, Mecker Moller, Igor Puzanov, C Lance Cowey, Eric Whitman, Carmen Ballesteros-Merino, Shawn M. Jensen, Bernard A Fox, Emmett Schmidt, Clemens Krepler, Scott Diede, Erica Browning, Reneta Hermiz, Lauren Svenson, Jon Salazar, Jack Lee, Christopher Baker, Donna Bannavong, Jendy Sell, Kellie Malloy Foerter, David Canton, Sandra Aung, Christopher Twitty, Alain Algazi, and Adil Daud
A novel surgeon credentialing and quality assurance process using transoral surgery for oropharyngeal cancer in ECOG-ACRIN Cancer Research Group Trial E3311., Robert L Ferris, Yael Flamand, F Christopher Holsinger, Gregory S Weinstein, Harry Quon, Ranee Mehra, Joaquin J Garcia, Michael L Hinni, Neil D Gross, Erich M Sturgis, Umamaheswar Duvvuri, Eduardo Méndez, John A Ridge, J Scott Magnuson, Kerry A Higgins, Mihir R Patel, Russel B Smith, Daniel W Karakla, Michael E Kupferman, James P Malone, Benjamin L Judson, Jeremy Richmon, Jay O Boyle, Rodrigo Bayon, Bert W O'Malley, Enver Ozer, Giovana R Thomas, Wayne M Koch, Richard Bryan Bell, Nabil F Saba, Shuli Li, Elin R Sigurdson, and Barbara Burtness
Transoral robotic surgical resection followed by randomization to low- or standard-dose IMRT in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN Cancer Research Group (E3311)., Robert L. Ferris, Yael Flamand, Gregory S. Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J. Garcia, Christine H. Chung, Maura L. Gillison, Umamaheswar Duvvuri, Bert W. O'Malley, Enver Ozer, Giovanna R. Thomas, Wayne Koch, Michael Elliot Kupferman, Richard Bryan Bell, Nabil F. Saba, Miriam Lango, Eduardo Mendez, and Barbara Burtness
Cancer vaccines yesterday, today, and tomorrow: Cinderella no more?, Bernard A Fox
Immunotherapy-induced anti-cancer responses, Bernard A Fox
Immunotherapy-Induced Anti-Cancer Responses, Bernard A Fox
443 An immunotherapy trio in advanced HNSCC for coordinated B and T cell antigen response, Bernard A Fox, Tarsem Moudgil, Traci Hilton, Noriko Iwamoto, Christopher Paustian, Adi Mehta, Fridtjof Lund-Johansen, Rachel E Sanborn, Richard Bryan Bell, Madeleine Laws, Glenna McDonnell, Yoshinobu Koguchi, Carlo Bifulco, Brian D. Piening, Carmen Ballesteros-Merino, Shawn M. Jensen, Takashi Shimada, Hong-Ming Hu, Walter Urba, Rom Leidner, and Marcus Couey
443 An immunotherapy trio in advanced HNSCC for coordinated B and T cell antigen response, Bernard A Fox, Tarsem Moudgil, Traci Hilton, Noriko Iwamoto, Christopher Paustian, Adi Mehta, Fridtjof Lund-Johansen, Rachel E Sanborn, Richard Bryan Bell, Madeline Laws, Glenna McDonnell, Yoshinobu Koguchi, Carlo Bifulco, Brian D. Piening, Carmen Ballesteros-Merino, Shawn M. Jensen, Takashi Shimada, Hong-Ming Hu, Walter Urba, Rom Leidner, and Marcus Couey
Immunoscore as a parameter predicting time to recurrence and disease-free survival in T4N0 stage II colon cancer patients., Jerome Galon, Fabienne Hermitte, Bernhard Mlecnik, Alessandro Lugli, Carlo Bifulco, Iris D. Nagtegaal, Arndt Hartmann, Florence Marliot, Marc Van Den Eynde, Michael H.A. Roehrl, Pamela S. Ohashi, Eva Zavadova, Toshihiko Torigoe, Prabhudas S. Patel, Yili Wang, Yutaka Kawakami, Francesco Marincola, Paolo Antonio Ascierto, Bernard A Fox, and Franck Pages
1074TiP SGNTGT-001: A phase I study of SGN-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies, E Garralda, Rachel E Sanborn, AR Minchom, D Davar, G Curigliano, V Ribrag, A Mehta, F Foss, P Garfin, and S Ansell
Safety and Clinical Activity of MEDI0562, a Humanized OX40 Agonist Monoclonal Antibody, in Adult Patients with Advanced Solid Tumors., Bonnie S Glisson, Rom Leidner, Robert L Ferris, John Powderly, Naiyer A Rizvi, Bhumsuk Keam, Reva Schneider, Sanjay Goel, James P Ohr, Jennifer Burton, Yanan Zheng, Steven Eck, Matthew Gribbin, Katie Streicher, Danielle M Townsley, and Sandip Pravin Patel
Outcomes of Treatment with the Chimeric Antigen Receptor (CAR) T Cell Therapy Lisocabtagene Maraleucel (liso-cel) in the Nonuniversity Setting: Initial Results from the Outreach Study, John E Godwin, Cesar O. Freytes, Michael Maris, Don A. Stevens, Daanish Hoda, Bassam Mattar, Juan C. Varela, Mohamad Cherry, James Essell, Jay Courtright, Suzanne R. Fanning, Habte A. Yimer, Nikolaus S. Trede, Marina Youssef, James Lymp, and Carlos Bachier
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors., Jonathan Wade Goldman, Sarina Anne Piha-Paul, Brendan Curti, Katrina Pedersen, Todd Michael Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Scott A. Hammond, Katie Streicher, Danielle Michelle Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, and John D. Powderly
Safety and tolerability of MEDI0562 in combination with durvalumab or tremelimumab in patients with advanced solid tumors., Jonathan Wade Goldman, Sarina Anne Piha-Paul, Brendan Curti, Katrina Pedersen, Todd Michael Bauer, Stefanie L. Groenland, Richard D. Carvajal, Vaishali Chhaya, Scott A. Hammond, Katie Streicher, Danielle Michelle Townsley, Young Kwang Chae, Jens Voortman, Aurelien Marabelle, and John D. Powderly
CT191 - Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC, Jonathan W. Goldman, Terrence L. Fisher, Elizabeth Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Andreas Schroder, Kevin Chin, Michael Shafique, Thaddeus Beck, Megan A. Baumgart, Ramaswamy Govindan, Nashat Gabrail, Rachel E Sanborn, Alexander Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, and Maurice Zauderer
Abstract CT191: Interim results from CLASSICAL-Lung, phase 1b/2 study of pepinemab (VX15/2503) in combination with avelumab in advanced NSCLC, Jonathan W. Goldman, Terrence L. Fisher, Elizabeth Evans, John E. Leonard, Desa Rae Pastore, Crystal Mallow, Ernest Smith, Andreas Schroeder, Kevin Chin, Michael Shafique, Thaddeaus Beck, Megan A. Baumgart, Ramaswamy Govindan, Nashat Gabrail, Rachel E Sanborn, Alexander I. Spira, Nagashree Seetharamu, Yanyan Lou, Aaron S. Mansfield, and Maurice Zauderer
Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy., Michael J. Gough, Shay Sharon, Marka R Crittenden, and Kristina H Young
Using Preclinical Data to Design Combination Clinical Trials of Radiation Therapy and Immunotherapy., Michael J. Gough, Shay Sharon, Marka R Crittenden, and Kristina H Young
A phase II single-arm study of pembrolizumab with enzalutamide in men with metastatic castration-resistant prostate cancer progressing on enzalutamide alone., Julie N Graff, Tomasz M Beer, Joshi J Alumkal, Rachel E Slottke, William L. Redmond, George V Thomas, Reid F Thompson, Mary A Wood, Yoshinobu Koguchi, Yiyi Chen, Emile Latour, Raymond C Bergan, Charles G Drake, and Amy E Moran
Conserved Interferon-γ Signaling Drives Clinical Response to Immune Checkpoint Blockade Therapy in Melanoma., Catherine S Grasso, Jennifer Tsoi, Mykola Onyshchenko, Gabriel Abril-Rodriguez, Petra Ross-Macdonald, Megan Wind-Rotolo, Ameya Champhekar, Egmidio Medina, Davis Y Torrejon, Daniel Sanghoon Shin, Phuong Tran, Yeon Joo Kim, Cristina Puig-Saus, Katie Campbell, Agustin Vega-Crespo, Michael Quist, Christophe Martignier, Jason J Luke, Jedd D Wolchok, Douglas B Johnson, Bartosz Chmielowski, F Stephen Hodi, Shailender Bhatia, William Sharfman, Walter Urba, Craig L Slingluff, Adi Diab, John B A G Haanen, Salvador Martin Algarra, Drew M Pardoll, Valsamo Anagnostou, Suzanne L Topalian, Victor E Velculescu, Daniel E Speiser, Anusha Kalbasi, and Antoni Ribas
Germinal centers in tertiary lymphoid structures distinguish long-term pancreatic cancer survivors associated with neoantigen expression and immune memory, Andrew J Gunderson
TGFβ suppresses CD8+ T cell expression of CXCR3 and tumor trafficking., Andrew J Gunderson, Tomoko Yamazaki, Kayla McCarty, Nathaniel E Fox, Michaela Phillips, Alejandro F Alice, Tiffany Blair, Mark Whiteford, David O'Brien, Rehan Ahmad, Maria X Kiely, Amanda Hayman, Todd Crocenzi, Michael J. Gough, Marka R. Crittenden, and Kristina H Young
Initial and Consolidation Therapy for Younger Patients with Mantle Cell Lymphoma., Daniel Guy and Brad S Kahl
Results of Lung Cancer Screening in the Community., John R Handy, Michael Skokan, Erika Rauch, Steven Zinck, Rachel E Sanborn, Svetlana Kotova, and Mansen Wang
Results of Lung Cancer Screening in the Community., John R Handy, Michael Skokan, Erika Rauch, Steven Zinck, Rachel E Sanborn, Svetlana Kotova, and Mansen Wang
Three-Dimensional Computer-Assisted Surgical Planning, Manufacturing, and Intraoperative Navigation in Oncologic Surgery., Phillip Harrison, Ashish Patel, Allen C Cheng, and Richard Bryan Bell
Simultaneously spatial and temporal Higher-Order Total Variations for noise suppression and motion reduction in DCE and IVIM., Renjie He, Yao Ding, Abdallah S R Mohamed, Sweet Ping Ng, Rachel B Ger, Hesham Elhalawani, Baher A Elgohari, Kristina H Young, Katherine A Hutcheson, Clifton D Fuller, and Stephen Y Lai
Transcriptomic Profiling of Human Effector and Regulatory T Cell Subsets Identifies Predictive Population Signatures., Barbara Höllbacher, Thomas Duhen, Samantha Motley, Maria M Klicznik, Iris K Gratz, and Daniel J Campbell
SITC cancer immunotherapy resource document: a compass in the land of biomarker discovery., Siwen Hu-Lieskovan, Srabani Bhaumik, Kavita Dhodapkar, Jean-Charles J B Grivel, Sumati Gupta, Brent A Hanks, Sylvia Janetzki, Thomas O Kleen, Yoshinobu Koguchi, Amanda W Lund, Cristina Maccalli, Yolanda D Mahnke, Ruslan D Novosiadly, Senthamil R Selvan, Tasha Sims, Yingdong Zhao, and Holden T Maecker
Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus-negative oral squamous cell carcinomas with negative resection margins., Lauren Hum, Daniel Bethmann, Zipei Feng, Shu-Ching Chang, Alexander Eckert, Carmen Ballesteros-Merino, Claudia Keschke, Matthias Kappler, Carlo Bifulco, Claudia Wickenhauser, Barbara Seliger, Bernard A Fox, and Richard Bryan Bell
Examining the Impact of the 2019 Novel Coronavirus and Pandemic-Related Hardship on Adverse Pregnancy and Infant Outcomes: Design and Launch of the HOPE COVID-19 Study, Laura L. Jelliffe-Pawlowski, Scott P. Oltman, Larry Rand, Karen A. Scott, Miriam Kuppermann, Rebecca Baer, April Bell, Gretchen Bandoli, Jean Costello, Nadia Diamond-Smith, Elissa Epel, Rebecca Jackson, Fei Jiang, Deborah A. Karasek, Christina Lindan, Allison O'Leary, Jeffrey Olgin, Matt Pantell, Alison Paquette, Nisha Parikh, Noah Peyser, Xianhua Piao, Aric Prather, George Rutherford, Kelli K. Ryckman, Martina Steurer-Muller, Jodi Stookey, Ganapati Srinivasa, Hollis Wright, Charles E. McCulloch, Brian D. Piening, Elizabeth E. Rogers, and Christina Chambers
480 Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12, Shawn M. Jensen, Christopher Twitty, Christopher Paustian, Madelein Laws, Glenna McDonnell, Keith W Wegman, Tarsem Moudgil, Michael E Afentoulis, Mia Han, Kellie Malloy Foerter, David Canton, Jack Lee, Bianca Nguyen, John Rodriguez, Kim Jaffe, Brian D. Piening, Carlo Bifulco, Daniel O'Connor, Walter Urba, Rom Leidner, Traci Hilton, Hong-Ming Hu, and Bernard A Fox
480 Preliminary evaluation of a novel coronavirus vaccine (CORVax) using electroporation of plasmid DNA encoding a stabilized prefusion SARS-CoV-2 spike protein alone or with transfection of plasmid IL-12, Shawn M. Jensen, Christopher Twitty, Christopher Paustian, Madelein Laws, Glenna McDonnell, Keith W Wegmann, Tarsem Moudgil, Michael E Afentoulis, Mia Han, Kellie Malloy Foerter, David Canton, Jack Lee, Biance Nguyen, John Rodriguez, Kim Jaffe, Brian D. Piening, Carlo Bifulco, Daniel O'Connor, Walter Urba, Rom Leidner, Traci Hilton, Hong-Ming Hu, and Bernard A Fox
CX-2029, a PROBODY drug conjugate targeting CD71 (transferrin receptor): Results from a first-in-human study (PROCLAIM-CX-2029) in patients (Pts) with advanced cancer., Melissa Lynne Johnson, Anthony B. El-Khoueiry, Navid Hafez, Nehal J. Lakhani, Hirva Mamdani, Jordi Rodon Ahnert, Rachel E Sanborn, Thang Ho, Rachel Li, Jana Waldes, and Alexander I. Spira
Noninvasive biomarkers for prediction and diagnosis of heart transplantation rejection., Yeraz Khachatoorian, Vahe Khachadourian, Eleanor Chang, Erick R Sernas, Elaine F Reed, Mario Deng, Brian D. Piening, Alexandre C Pereira, Brendan Keating, and Martin Cadeiras
Inflammatory and clinical risk factors for chemotherapy-induced peripheral neuropathy (CIPN): A nationwide longitudinal study in 143 cancer patients during chemotherapy., Ian Kleckner, Todd Jusko, Eva Culakova, Amber Kleckner, Matthew Asare, Julia Ellen Inglis, Kah Poh Loh, Luke Joseph Peppone, Jeffrey L. Berenberg, Alison Conlin, Deborah J. Ossip, and Karen Michelle Mustian
760 Trough levels of ipilimumab in serum as a potential predictive biomarker of clinical outcomes for patients with advanced melanoma after treatment with ipilimumab, Yoshinobu Koguchi, Noriko Iwamoto, Takashi Shimada, Shu-Ching Chang, John Cha, Brian D. Piening, Brendan Curti, Walter Urba, and William L. Redmond
